[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Pingping Song\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":39},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":5},"100498101","phase-2-neoadjuvant-wx-0593-in-resectable-alk-positive-or-ros1-positive-non-small-cell-lung-cancer-100498101",false,"NCT05765877","Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer","Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer : a Single-arm, Exploratory Trial","Inclusion Criteria:\n\n* Histologically confirmed non-small cell lung cancer (NSCLC).\n* ALK-positive or ROS1-positive NSCLC in Stage IB-IIIA (according to the 8th American Joint Committee on Cancer TNM edition), as assessed by investigator.\n* Complete surgical resection of the primary NSCLC must be deemed achievable, as assessed by a MDT evaluation (which should include a thoracic surgeon, specialized in oncologic procedures).\n* ECOG Performance Status of 0-1.\n* At least one measurable lesion according to RECIST 1.1.\n* Adequate organ and marrow function.\n\nExclusion Criteria:\n\n* Prior treatment with any systemic anti-cancer therapy for NSCLC including chemotherapy, biologic therapy, immunotherapy, or any investigational drug.\n* Prior treatment with ALK TKI or ROS1 TKI.\n* Prior treatment with local radiotherapy.\n* Mixed small cell and NSCLC histology.\n* Patients who are candidates to undergo only segmentectomies or wedge resections.","ALL","18 Years",{"count":19,"type":20},26,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This is a single-arm, exploratory trial to evaluate the efficacy and safety of neoadjuvant WX-0593 in patients with resectable ALK-positive or ROS1- positive non-small cell lung cancer(NSCLC).",[26],"Non-Small Cell Lung Cancer(NSCLC)","RECRUITING","2025-06-11",{"date":30,"type":31},"2025-06-12","ACTUAL",{"date":33,"type":31},"2023-03-01",{"date":35,"type":20},"2029-03",{"name":37,"class":38},"Pingping Song","OTHER",""]